Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth Opportunities

Core Viewpoint - Perimeter Medical Imaging AI, Inc. reported preliminary unaudited revenues for Q2-2025, indicating significant growth and management changes, alongside the establishment of an Industry Advisory Board to support future growth strategies [1][3][5]. Financial Performance - Total revenue for Q2-2025 is anticipated to be approximately $500,000, reflecting a year-over-year growth of about 100% [3]. - The company expects over 35% growth in procedures, leading to more than 50% growth in recurring revenue compared to Q1-2025, driven by increased utilization of the Perimeter S-Series system [3]. - For the six-month period ending June 30, 2025, total revenue is projected to be around $1.0 million, compared to $345,000 for the same period in 2024 [4]. - Gross margin is expected to be approximately 69% for Q2-2025 and 61% for the six-month period ending June 30, 2025 [4]. Management Changes - Abbey Goodman has been appointed as Vice President of Sales, bringing over 20 years of medical device sales experience [7]. - Paolo DiPasquale has been appointed as Vice President of Corporate Development, with over 17 years of experience in capital markets [8]. - Tom Boon has retired as Chief Operating Officer but will continue to contribute to the company’s strategy through the newly formed Industry Advisory Board [9]. Industry Advisory Board - The newly created Industry Advisory Board will be chaired by Diana Chan, who has over 20 years of experience in the medical device industry [10]. - The board aims to support the company's growth strategies across various products and markets [10][11]. Future Outlook - The company anticipates initial savings from cost control efforts, projecting a 30% reduction in total operating costs starting in Q3-2025 [5]. - The sales pipeline is expected to continue building, with the Premarket Approval application for the next-generation Perimeter B-Series under review with the FDA [5].